Old Levothyrox to be Reintroduced in France

(c) Lena Lir/shutterstock
(c) Lena Lir/shutterstock

An older version of a thyroid drug made by Merck Serono is planned to be reintroduced in France after more than 9,000 of the country's three million users complained of serious side effects such as cramps, headaches, dizziness and hair loss from a new formula launched in March of this year.

The French drug approval agency Agence Francaise du Medicament had asked the German company to develop the new formula, which is said to be stabler than the old version.

Merck said the new version of Levothyrox is set to be approved in other European countries.

Levothyrox is prescribed to treat underactive thyroids or following surgery for cancer of the organ. News reports said France is the world's leading consumer of this treatment and the first country in which the new version was introduced.

Only one alternative is currently available in France, L-Thyroxine, manufactured by a Sanofi subsidiary. Health Minister Agnes Buzyn told France Inter radio that "alternatives, other brands, other drugs" will be available in a month.

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.